Abstract:Objective: The objective of this study was to examine the preparation process of DSPE-PEG-C60/NCTD micelles and assess the impact of fullerenol (C60)-modified micelles on the nephrotoxicity and antitumor activity of NCTD. Method: The micelles containing NCTD were prepared using the ultrasonic method and subsequently optimized and characterized. The cytotoxicity of micelles loaded with NCTD was assessed using the CCK-8 method on human hepatoma cell lines HepG2 and BEL-7402, as well as normal cell lines HK-2 and L02. Acridine orange/ethidium bromide (AO/EB) double staining and flow cytometry were employed to assess the impact of NCTD-loaded micelles on the apoptosis of the HK-2 cells and the HepG2 cells. Additionally, JC-1 fluorescence was utilized to quantify the alterations in mitochondrial membrane potential. The generation of reactive oxygen species (ROS) following micelle treatment was determined through 2′,7′-dichlorofluorescein diacetate (DCFDA) staining. Results: The particle size distribution of the DSPE-PEG-C60/NCTD micelles was determined to be 91.57 nm (PDI = 0.231). The zeta potential of the micelles was found to be −13.8 mV. The encapsulation efficiency was measured to be 91.9%. The in vitro release behavior of the micelles followed the Higuchi equation. Cellular experiments demonstrated a notable decrease in the toxicity of the C60-modified micelles against the HK-2 cells, accompanied by an augmented inhibitory effect on cancer cells. Compared to the free NCTD group, the DSPE-PEG-C60 micelles exhibited a decreased apoptosis rate (12%) for the HK-2 cell line, lower than the apoptosis rate observed in the NCTD group (36%) at an NCTD concentration of 75 μM. The rate of apoptosis in the HepG2 cells exhibited a significant increase (49%), surpassing the apoptosis rate observed in the NCTD group (24%) at a concentration of 150 μM NCTD. The HK-2 cells exhibited a reduction in intracellular ROS and an increase in mitochondrial membrane potential (ΔψM) upon exposure to C60-modified micelles compared to the NCTD group. Conclusions: The DSPE-PEG-C60/NCTD micelles, as prepared in this study, demonstrated the ability to decrease cytotoxicity and ROS levels in normal renal cells (HK-2) in vitro. Additionally, these micelles showed an enhanced antitumor activity against human hepatocellular carcinoma cells (HepG2, BEL-7402).

Liposomal Nanodrug Based on Norcantharidin Derivative for Increased in Vivo Activity

Preclinical evaluations of Norcantharidin liposome and emulsion hybrid delivery system with improved encapsulation efficiency and enhanced antitumor activity

Preparation and characterization of norcantharidin liposomes modified with stearyl glycyrrhetinate.

Norcantharidin Blocks Wnt/β-catenin Signaling Via Promoter Demethylation of WIF-1 in Glioma.

Strategies for Solubility and Bioavailability Enhancement and Toxicity Reduction of Norcantharidin

Targeting of the B-Lineage Leukemia Stem Cells and Their Progeny with Norcantharidin Encapsulated Liposomes Modified with A Novel Cd19 Monoclonal Antibody 2e8 in Vitro

Anticancer activity and mechanisms of norcantharidin-Nd3II on hepatoma.

Promising positive liver targeting delivery system based on arabinogalactan-anchored polymeric micelles of norcantharidin

Targeted acid-labile conjugates of norcantharidin for cancer chemotherapy

Preparation of a Novel Liver-Targeting Nanoparticle of Norcantharidin Derivative and Evaluation of Its Anti-Tumour Activity

Nanodelivery of a Self-Assembling Prodrug with Exceptionally High Drug Loading Potentiates Chemotherapy Efficacy.

Norcantharidin-Encapsulated C60-Modified Nanomicelles: A Potential Approach to Mitigate Cytotoxicity in Renal Cells and Simultaneously Enhance Anti-Tumor Activity in Hepatocellular Carcinoma Cells

Preparation and Evaluation of Norcantharidin-Encapsulated Liposomes Modified with a Novel CD19 Monoclonal Antibody 2E8.

Tumor-targeted hyaluronic acid-mPEG modified nanostructured lipid carriers for cantharidin delivery: An in vivo and in vitro study

Norcantharidin-Associated Galactosylated Chitosan Nanoparticles For Hepatocyte-Targeted Delivery

Multifunctional self-assembled micelles of galactosamine-hyaluronic acid-vitamin E succinate for targeting delivery of norcantharidin to hepatic carcinoma

Folate receptor-targeted liposomes loaded with a diacid metabolite of norcantharidin enhance antitumor potency for H22 hepatocellular carcinoma both in vitro and in vivo.

Transforming a Toxic Drug into an Efficacious Nanomedicine Using a Lipoprodrug Strategy for the Treatment of Patient-Derived Melanoma Xenografts.

Use of different ligand modification liposomes to evaluate the anti-liver tumor activity of cantharidin

Norcantharidin Analogues — Synthesis and Evaluation of Growth Inhibition in a Panel of Selected Tumor-Cell Lines

Nanoemulsion based lipid nanoparticles for effective demethylcantharidin delivery to cure liver cancer